MXPA05009986A - Tratamiento de la enfermedad de alzheimer. - Google Patents

Tratamiento de la enfermedad de alzheimer.

Info

Publication number
MXPA05009986A
MXPA05009986A MXPA05009986A MXPA05009986A MXPA05009986A MX PA05009986 A MXPA05009986 A MX PA05009986A MX PA05009986 A MXPA05009986 A MX PA05009986A MX PA05009986 A MXPA05009986 A MX PA05009986A MX PA05009986 A MXPA05009986 A MX PA05009986A
Authority
MX
Mexico
Prior art keywords
disease
ifn
combination
demens
medicaments
Prior art date
Application number
MXPA05009986A
Other languages
English (en)
Inventor
Luigi Grimaldi
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of MXPA05009986A publication Critical patent/MXPA05009986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se relaciona con el uso de un Interferon-( (IFN-() para tratar y para prevenir la enfermedad de Alzheimer (AD), la enfermedad de Creutzfeld-Jakob (CJD) o la enfermedad de Gerstmann-Straeussler-Scheinker (GSSD); se relaciona ademas con el uso del IFN-(, en combinacion con un agente para tratar la enfermedad de Alzheimer, para tratar y/o prevenir la enfermedad de Alzheimer; se prefiere el uso del IFN-( en combinacion con un inhibidor de la colinesterasa para tratar y/o prevenir la enfermedad de Alzheimer de inicio temprano.
MXPA05009986A 2003-03-19 2004-03-17 Tratamiento de la enfermedad de alzheimer. MXPA05009986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03100716 2003-03-19
PCT/EP2004/050316 WO2004082706A2 (en) 2003-03-19 2004-03-17 Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders

Publications (1)

Publication Number Publication Date
MXPA05009986A true MXPA05009986A (es) 2005-11-04

Family

ID=33016977

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009986A MXPA05009986A (es) 2003-03-19 2004-03-17 Tratamiento de la enfermedad de alzheimer.

Country Status (14)

Country Link
US (1) US20070110715A1 (es)
EP (1) EP1620124A2 (es)
JP (1) JP2006520368A (es)
KR (1) KR20050115279A (es)
CN (1) CN1791423A (es)
AR (1) AR043660A1 (es)
AU (1) AU2004222529A1 (es)
BR (1) BRPI0408491A (es)
CA (1) CA2516990A1 (es)
EA (1) EA009668B1 (es)
IL (1) IL170751A0 (es)
MX (1) MXPA05009986A (es)
NO (1) NO20054744L (es)
WO (1) WO2004082706A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005232447A1 (en) * 2004-04-14 2005-10-27 Warner-Lambert Company Llc Therapeutic combination for treatment of Alzheimers disease
US7695911B2 (en) * 2005-10-26 2010-04-13 Celera Corporation Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
WO2007107846A1 (en) * 2006-03-20 2007-09-27 Council Of Scientific And Industrial Research A pharmaceutical composition useful as acetyl cholinesterase inhibitors
CN101116670B (zh) * 2006-08-01 2010-11-10 广州和竺生物科技有限公司 可提供活性甲基或参与甲基转移的化合物作为制备治疗病毒性疾病的药的应用
CN101516401A (zh) * 2006-08-21 2009-08-26 诺瓦提斯公司 阿尔茨海默病进展的生物标记
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
US20110262407A1 (en) * 2008-11-11 2011-10-27 Targacept, Inc. Treatment with alpha7 selective ligands
US20110081428A1 (en) * 2009-09-16 2011-04-07 The Buck Institute For Age Research Use of thioflavin-like compounds to increase life span and/or health span
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
CN102382096A (zh) * 2011-09-06 2012-03-21 清华大学 异香豆素及其衍生物的制备方法
CN102707065A (zh) * 2012-03-23 2012-10-03 常熟市虞山绿茶有限公司 Prohibitin蛋白抗体在制备诊断老年性痴呆的试剂盒中的应用
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
US9116974B2 (en) * 2013-03-15 2015-08-25 Robert Bosch Gmbh System and method for clustering data in input and output spaces
CN106754995B (zh) * 2016-11-25 2020-07-10 山东农业大学 中华蜜蜂AccCDK5基因及AccCDK5r1基因及其应用
RU2729391C2 (ru) * 2018-12-28 2020-08-06 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Моноклональное антитело, способное нейтрализовать биологическую активность интерферона бета-1а человека
CN109518211B (zh) * 2019-01-08 2020-11-06 合肥工业大学 一种芳香偶酰类化合物的电化学合成方法
WO2023080687A1 (ko) * 2021-11-03 2023-05-11 가천대학교 산학협력단 아밀로이드 베타 멀티머 저해 약물의 고속 대량 스크리닝 방법 및 독소루비신 또는 이의 유도체를 포함하는 아밀로이드 베타의 올리고머화 또는 섬유화 억제용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057879A1 (en) * 1999-03-26 2000-10-05 Barry Reisberg Treatment of brain changes with myelin protective agents
IL150109A0 (en) * 1999-12-09 2002-12-01 Chiron Corp Method for administering a cytokine to the central nervous system and the lymphatic system

Also Published As

Publication number Publication date
EP1620124A2 (en) 2006-02-01
KR20050115279A (ko) 2005-12-07
EA009668B1 (ru) 2008-02-28
CA2516990A1 (en) 2004-09-30
EA200501479A1 (ru) 2006-02-24
CN1791423A (zh) 2006-06-21
AU2004222529A1 (en) 2004-09-30
AR043660A1 (es) 2005-08-03
WO2004082706A3 (en) 2005-01-13
BRPI0408491A (pt) 2006-04-04
JP2006520368A (ja) 2006-09-07
IL170751A0 (en) 2011-08-01
US20070110715A1 (en) 2007-05-17
NO20054744L (no) 2005-10-14
WO2004082706A2 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
GB0223040D0 (en) Therapeutic compounds
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
MXPA04000793A (es) Novedoso metodo terapeutico.
GB0225474D0 (en) Therapeutic agents
GB0025173D0 (en) Therapeutic agents
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
GB0223038D0 (en) Therapeutic compounds
IL160065A0 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
SI1663185T1 (sl) Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
EP1769791A3 (en) Treatment of Alzheimer's disease with cell cycle inhibitors
NO20035025D0 (no) Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
CY1107039T1 (el) Αναστολεις τριπεπτιδυλ πεπτιδασης
ATE423102T1 (de) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
HUP0300566A2 (hu) Galantamin alkalmazása az Alzheimer-kórral összefüggő neuropszichiátriai viselkedésformák terápiájában
AU2002354698A1 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
MXPA04001230A (es) Uso de inhibidores de il-18 en desordenes de hipersensibilidad.
WO2003094968A3 (en) Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
AU2003287513A8 (en) Inhibitors of beta-secretase, and their use for the prevention or treatment of alzheimer's disease or mild cognitive impairment